Beruflich Dokumente
Kultur Dokumente
Neet ss
SIEZURES
• risk factors associated with recurrent seizures include the following:
(1) an abnormalneurologic examination,
(2) seizures presenting as status epilepticus,
(3) postictal Todd’s paralysis,
(4) a strong family history of seizures,
(5) an abnormal EEG.
• Asian individuals carrying the human leukocyte antigen allele, HLA-
B*1502, are at particularly high risk of developing serious skin
reaceactions from carbamazepine and phenytoin.
• The most common surgical procedure for patients with temporal lobe
epilepsy involves resection of the anteromedial temporal lobe or
(amygdalohippocampectomy).
• corpus callosotomy has been shown to be effective for disabling tonic or
atonic seizures, usually when they are part of a mixed-seizure syndrome
(e.g., Lennox-Gastaut syndrome)
• “interictal personality.”
• other than topiramate, the newer antiepileptic drugs are far safer than
valproic acid.
• Monotherapy, lowest effective dose, folate (1–4 mg/d), especially during the
first trimester, oral vitamin K (20 mg/d, phylloquinone) in the last 2 weeks of
pregnancy, and the infant should receive intramuscular vitamin K (1 mg) at
birth.
AEDs
• Qt prolongation - esogabine , rufinamide
• PR prolongation – lacosamide
• Levels increased by CYP2C19 inhibitors – clobazam
• Renal stones – topiramate
• Stevens-Johnson syndrome – lamotrigine
CVA
• Stroke is the second leading cause of death worldwide
• The definition of TIA requires that all neurologic signs and symptoms resolve
within 24 h without evidence of brain infarction on brain imaging
• A decrease in cerebral blood flow to zero causes death of brain tissue within 4–
10 min; values <16–18 mL/100 g tissue per minute cause infarction within an
hour; and values <20 mL/100 g tissue per minute cause ischemia without
infarction unless prolonged for several hours or days
• CEREBRAL Edema peaks on the second or third day but can cause mass
effect for ~10 days. hemicraniectomy markedly reduces mortality
• NINDS study used IV rtPA (0.9 mg/kg to a 90-mg maximum; 10% as a bolus,
then the remainder over 60 min WITHIN 3hrs
• Symptomatic intracranial hemorrhage occurred in 6.4%
• (ECASS) III explored the safety and efficacy of rtPA in the 3- to 4.5-h time window
• The Prolyse in Acute Cerebral Thromboembolism (PROACT) II trial found benefit
for intraarterial prourokinase in acute MCA occlusions up to the sixth hour
following on set of stroke.
• Intraarterial administration of a thrombolytic agent for acute ischemic stroke (AIS)
is not approved by the U.S. Food and Drug Administration (FDA)
• SYNTHESIS trial- IV rtPA versus intraarterial rtPA for patients within 3 h of stroke
onset. No differences were found between the groups at 90 days.
• Neuroprotectives - multiple human trials, they have not yet been proven to
be beneficial.
• Hypothermia is a powerful neuroprotective treatment in patients with
cardiac arrest